Iron overload disrupts bone homeostasis via TfR1-dependent ferroptosis and cGAS/STING-driven pyroptosis in pyogenic spondylitis
-
By
-
Wenchao Xu
-
Qinpeng Xu
-
Hongdong Tan
-
Xiaodong Liu
-
Jiaju Ma
-
Fei Jia
-
Heng Yang
-
Meimei Zheng
-
Jianlong Li
-
Xingang Cui
-
Xingzhi Jing
-
Xiaoyang Liu
-
June 30, 2026
-
Clinical Scorecard: Iron Excess Impairs Bone Homeostasis through TfR1-Mediated Ferroptosis and cGAS/STING-Activated Pyroptosis in Pyogenic Spondylitis
At a Glance
| Category | Detail |
|---|
| Condition | Pyogenic Spondylitis |
| Key Mechanisms | Iron overload, TfR1-mediated ferroptosis, cGAS/STING-activated pyroptosis |
| Target Population | Patients with pyogenic spondylitis |
| Care Setting | Clinical research and therapeutic development |
Key Highlights
- Iron overload is associated with bone destruction in pyogenic spondylitis.
- TfR1 expression is elevated in infected vertebral specimens.
- Ferroptosis and pyroptosis contribute to impaired osteogenesis.
- Ferristatin II reduces iron deposition and preserves trabecular architecture.
- Targeting TfR1-mediated iron influx may offer new therapeutic strategies.
Guideline-Based Recommendations
Diagnosis
- Evaluate iron levels and TfR1 expression in patients with pyogenic spondylitis.
Management
- Consider iron chelation therapy and TfR1 inhibitors for treatment.
Monitoring & Follow-up
- Monitor bone health and iron levels in patients undergoing treatment.
Risks
- Iron overload may lead to increased bone destruction and neurological complications.
Patient & Prescribing Data
Patients diagnosed with pyogenic spondylitis experiencing bone loss.
Use of iron chelators like DFO and TfR1 inhibitors may mitigate bone loss.
Clinical Best Practices
- Assess iron status in patients with pyogenic spondylitis.
- Implement strategies to manage iron overload in clinical settings.
- Investigate the role of ferroptosis in other inflammatory bone diseases.
Related Resources & Content
